Nivalis Therapeutics (NASDAQ: ALPN) is one of 291 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Nivalis Therapeutics to related companies based on the strength of its dividends, profitability, institutional ownership, earnings, analyst recommendations, risk and valuation.
This table compares Nivalis Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nivalis Therapeutics Competitors||-5,182.24%||-428.32%||-40.70%|
This is a summary of recent ratings for Nivalis Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nivalis Therapeutics Competitors||793||3135||11398||229||2.71|
Nivalis Therapeutics presently has a consensus price target of $7.31, suggesting a potential downside of 27.96%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.68%. Given Nivalis Therapeutics’ peers stronger consensus rating and higher possible upside, analysts clearly believe Nivalis Therapeutics has less favorable growth aspects than its peers.
Risk & Volatility
Nivalis Therapeutics has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Nivalis Therapeutics’ peers have a beta of 0.99, meaning that their average share price is 1% less volatile than the S&P 500.
Insider & Institutional Ownership
50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 9.8% of Nivalis Therapeutics shares are owned by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Nivalis Therapeutics and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Nivalis Therapeutics||N/A||-$31.46 million||-0.88|
|Nivalis Therapeutics Competitors||$290.00 million||$35.57 million||150.30|
Nivalis Therapeutics’ peers have higher revenue and earnings than Nivalis Therapeutics. Nivalis Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Nivalis Therapeutics peers beat Nivalis Therapeutics on 10 of the 12 factors compared.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company’s S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company’s lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.